Nasdaq
$25.76▼ 0.73%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.23BShares out 47.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
32- 1d agoAfter-hours26.10.24 05:304Ownership#●●●
Rapport Therapeutics, Inc.
Insider Abraham Ceesay of Rapport Therapeutics, Inc. filed a Form 4 on October 23, 2026, reporting changes in beneficial ownership of securities effective October 21, 2026. This filing formalizes the recent transaction activity regarding the executive's holdings.…more
$25.76-0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 05:014Ownership
Rapport Therapeutics, Inc.
Rapport Therapeutics insider Ramiro Sanchez filed a Form 4 on October 23, 2026, reporting changes in beneficial ownership of securities. This filing discloses updates regarding the company's insider holdings.…more
$25.76-0.73%vs prev closeView filingShare - 2d agoAfter-hours26.10.23 05:574Ownership
Rapport Therapeutics, Inc.
Insider Paul M. Silva of Rapport Therapeutics, Inc. filed a Form 4 report on October 22, 2026, disclosing changes in beneficial ownership of securities. This filing serves as an official record of the insider's updated equity holdings.…more
$25.76-0.73%vs prev closeView filingShare
31 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoRegular26.10.20 22:31Bullish#●●●#●●●
Rapport Therapeutics Shares Surge on Positive Phase 2 Bipolar Mania Trial Results…more
Rapport Therapeutics announced that its RAP-219 candidate met primary endpoints in a Phase 2 trial for acute bipolar mania, demonstrating statistical efficacy. The company has successfully achieved clinical proof-of-concept and plans to engage with the FDA for late-stage development.…more
$25.76-0.73%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoPre-market26.10.20 19:00
●●●●●●●● ●●●●● ●●●●●●
Rapport Therapeutics announced that its RAP-219 candidate met primary and secondary endpoints in a Phase 2 trial for bipolar mania with favorable safety data. The company plans to engage with the FDA to initiate Phase 3 trials in the second half of 2027.…more
$25.76-0.73%vs prev close - 9.2Pre-market26.09.02 20:00
●●●●●●●● ●●●●● ●●●●●●
Rapport Therapeutics announced that management will participate in two upcoming investor conferences in September. This is a routine corporate event announcement and does not provide new material information affecting the stock price.…more
$25.76-0.73%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report